Repositioning Candidate Details
| Candidate ID: | R0702 |
| Source ID: | DB05103 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | AN-9 |
| Synonyms: | Pivaloyloxymethyl butyrate; Pivaloyloxymethylbutyrate; Pivanex |
| Molecular Formula: | C10H18O4 |
| SMILES: | CCCC(=O)OCOC(=O)C(C)(C)C |
| Structure: |
|
| DrugBank Description: | Pivaloyloxymethyl butyrate (AN-9), an acyloxyalkyl ester prodrug of butyric acid (BA), exhibited low toxicity and significant anticancer activity in vitro and in vivo. It shows greater potency than BA at inducing malignant cell differentiation and tumor growth inhibition and has demonstrated more favorable toxicological, pharmacological, and pharmaceutical properties than BA in preclinical studies. |
| CAS Number: | 122110-53-6 |
| Molecular Weight: | 202.25 |
| DrugBank Indication: | Investigated for use/treatment in liver cancer, lung cancer, melanoma, and leukemia (lymphoid). |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Pivaloyloxymethyl butyrate is a histone deacetylase inhibitor analog of butyric acid that causes apoptosis of cancer cells through signaling cellular differentiation. It is rapidly and extensively transported intracellularly because of its high lipophilicity, where it undergoes esterase-mediated hydrolysis to form pivalic acid, formaldehyde, and BA. |
| Targets: | -- |
| Inclusion Criteria: | Therapeutic strategy associated |
